Blar i Bergen Open Research Archive på forfatter "Jordhøy, Marit Slaaen"
-
Geriatric assessment with management for older patients with cancer receiving radiotherapy. Protocol of a Norwegian cluster-randomised controlled pilot study
Røyset, Inga Marie; Saltvedt, Ingvild; Rostoft, Siri; Grønberg, Bjørn Henning; Kirkevold, Øyvind; Oldervoll, Line Merethe; Bye, Asta; Saltyte Benth, Jurate; Bergh, Sverre; Melby, Line; Halsteinli, Vidar; Døhl, Øystein; Røsstad, Tove Garåsen; Eriksen, Guro Falk; Sollid, May Ingvild Volungholen; Rolfson, Darryl; Jordhøy, Marit Slaaen (Journal article; Peer reviewed, 2021)About 50% of patients with cancer are expected to need radiotherapy (RT), and the majority of these are older. To improve outcomes for older patients with cancer, geriatric assessment (GA) with management (GAM) is highly ... -
Geriatric impairments are associated with reduced quality of life and physical function in older patients with cancer receiving radiotherapy - A prospective observational study
Eriksen, Guro Falk; Saltyte Benth, Jurate; Grønberg, Bjørn Henning; Rostoft, Siri; Kirkhus, Lene; Kirkevold, Øyvind; Oldervoll, Line Merethe; Bye, Asta; Hjelstuen, Anne Kristine; Jordhøy, Marit Slaaen (Journal article; Peer reviewed, 2023)Introduction: Quality of life (QoL) and function are important outcomes for older adults with cancer. We aimed to assess differences in trends in patient-reported outcomes (PROs) during radiotherapy (RT) between (1) groups ... -
The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
Isaksen, Kathrine Thuestad; Galleberg, Renate Berget; Mastroianni, Maria Adele; Rinde, Marit; Rusten, Leiv Sindre; Barzenje, Dlawer Abdulla; Ramslien, Lloyd Frode; Fluge, Øystein; Jordhøy, Marit Slaaen; Meyer, Peter Albert; Liestøl, Knut; Smeland, Erlend Bremertun; Lingjærde, Ole Christian; Holte, Harald; Brodtkorb, Marianne (Journal article; Peer reviewed, 2023)The International prognostic Index (IPI) is the most widely used clinical prediction model for diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone ...